

## AMENDMENT TO THE CLAIMS

**Listing of the claims:** This listing of claims replaces all prior versions, and listings of claims in the application:

1-36. (Canceled).

37. (Currently Amended) A method for suppressing an ongoing autoimmune response associated with a cell mediated autoimmune disease in a rodent or human host said disease, the method comprising administering by nose ~~or mouth~~ to said host an effective amount for suppressing said response of a composition comprising a bystander antigen, wherein said bystander antigen is not an antigen to which T cells of said host which mediate the disease are sensitized and wherein said bystander antigen is not an insulin antigen, and wherein said bystander antigen is present to ~~in~~ an organ or tissue afflicted by immune attack during said disease.

38-41. (Canceled).

42. (Previously Presented) The method of claim 37 wherein said bystander is administered to said host in aerosol form.

43. (Previously Presented) The method of claim 37 wherein said bystander antigen is administered in a dry powder form.

44. (Previously Presented) The method of claim 37 wherein said bystander antigen is administered as a saline solution.

45-47. (Canceled).

48. (Previously Presented) A pharmaceutical dosage form for suppressing an autoimmune disease in a human or rodent by suppressing an ongoing autoimmune response associated with said disease, the form consisting essentially of:

an effective amount for suppressing said response of a bystander antigen; and

a pharmaceutically acceptable carrier or diluent;

wherein said bystander antigen is not insulin nor an antigen to which T cells that mediate said disease in said host are sensitized, and wherein said dosage form is contained in an inhaler or nebulizer, and wherein said bystander antigen is specified to an organ or tissue afflicted by immune attack during said disease.

49-51. (Canceled).

52. (Currently Amended) The pharmaceutical dosage form of claim 48 49 wherein said dosage form is an aerosol form.

53. (Currently Amended) The pharmaceutical dosage form of claim 48 49 wherein said dosage form is a saline solution.

54. (Currently Amended) The pharmaceutical dosage form of claim 48 49 wherein said dosage form is a dry powder.

55. (Canceled).

56. (Previously Presented) The pharmaceutical dosage form of claim 48 wherein said disease is selected from the group consisting of Type I diabetes and animal models thereof and said bystander antigen is glucagon.

57. (Previously Presented) A pharmaceutical dosage form for nasal administration for suppressing Type I diabetes in a human comprising an effective amount for suppressing said type I diabetes of glutamic acid decarboxylase and a pharmaceutically acceptable carrier or diluent in an inhaler or nebulizer.

58-65. (Canceled).

66. (New) The method of claim 37 wherein said bystander is administered to the buccal mucosa of said host by inhalation.

67. (New) The method of claim 37 wherein said bystander is glucagon.

68. (New) The method of claim 37 wherein said bystander is glutamic acid decarboxylase.

69. (New) The method of claim 37 wherein said bystander antigen is purified.

70. (New) The method of claim 37 wherein said bystander antigen is pure.

71. (New) The pharmaceutical dosage form of claim 48 wherein said bystander antigen is purified.

72. (New) The pharmaceutical dosage form of claim 48 wherein said bystander antigen is pure.